GlobeNewswire

Invitation to the presentation of ALK’s first nine months (Q3) 2026 results on Tuesday, 17 November 2026
10/11/2026
ALK (ALKB:DC / Nasdaq Copenhagen: ALK B) will publish its results for the first nine months (Q3) of 2026 in the afternoon on Tuesday, 17 November 2026. The company will host a presentation for investors and analysts at [...]
Zus Health Raises $33 Million in Series B Funding to Accelerate the Next Generation of Connected Healthcare
10/11/2026
Led by Drive Capital, the financing brings total funding to more than $100 million and will accelerate Zus's AI-native healthcare data platform, powered by nationwide connectivity and built for intelligent clinical [...]
Decoy Therapeutics Named “R&D Solution of the Year” in 2026 BioTech Breakthrough Awards
10/11/2026
Recognition highlights the IMP³ACT™ platform and Designable Multi-Antivirals (D-MAVs), single drugs designed to work across many viruses CAMBRIDGE, Mass., Nov. 10, 2026 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. ( [...]
Beacon Behavioral Partners Expands Houston Presence Through Partnership With One Behavioral
10/11/2026
Six-location practice strengthens Beacon’s growing network across Houston, Dallas-Fort Worth and Austin PLANO, Texas, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Beacon Behavioral Partners (BBP), a growing national network of [...]
Thanks, Birth Control Day Brings Real Stories and Accurate Information to Young People’s Social Media Feeds to Combat Misinformation
10/11/2026
Power to Decide’s 14th annual campaign meets the moment with new data and an invitation to share what birth control has made possible. Washington, D.C., Nov. 10, 2026 (GLOBE NEWSWIRE) -- On Thursday, November 12, Power [...]
Ozari Health Publishes 2026 Compounded Tirzepatide Price Report: Monthly Costs Range From $125 to $199 Across Seven Online Providers
10/11/2026
Compiled from each provider's published prices on October 19, 2026, the report finds that the lowest regular monthly price for compounded tirzepatide on plans of three months or less runs from $125 to $199, that twelve- [...]
Levicept Presents New Data from Phase II Trial of LEVI-04, a Novel Non-Opioid Investigational Treatment for Osteoarthritis at ACR Convergence 2026
10/11/2026
Ex vivo data demonstrated LEVI-04 provides analgesia by inhibition of NT-3 Data deepen understanding of novel mechanism of action in osteoarthritis (OA), providing analgesia while preserving the physiological NGF [...]
Science 37 Named a BioSpace 2027 Best Place to Work
10/11/2026
Recognition celebrates the people behind its Direct-to-Patient Site model, the innovative, radically transparent culture, and the company's commitment to clinical quality MORRISVILLE, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE [...]
RECORDATI FIRST NINE MONTHS 2026: NET REVENUE +7.5%, EBITDA +7.7%, ADJUSTED NET INCOME +6.4%
10/11/2026
Consolidated net revenue of € 2,103.7 million in the first nine months of 2026, +7.5% or +9.4% on a like-for-like basis (3) at constant exchange rates (CER); adverse FX impact of € 35.6 million (-1.8%) EBITDA (1) of € [...]
ORYZON Reports Third Quarter 2026 Financial Results and Provides Corporate Update
10/11/2026
Updated clinical data from three iadademstat studies to be presented at ASH 2026, including encouraging results from ALICE-2 in first-line AML (95% ORR, 84% CRc and 74% CR) and FRIDA in relapsed/refractory FLT3-mutated [...]
CHRISTUS Health among nation's most digitally advanced health systems
10/11/2026
National recognition underscores CHRISTUS Health's commitment to using technology and innovation to enhance patient outcomes and support clinicians IRVING, Texas, Nov. 10, 2026 (GLOBE NEWSWIRE) -- CHRISTUS Health [...]
EssilorLuxottica: Nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2026
10/11/2026
Nombre total de droits de vote et d’actions composant le capital social au 31 octobre 2026 (Conformément à l’article L.233-8 II du Code de Commerce et aux articles 221-1 et 223-16 du Règlement Général de l’AMF) Paris, [...]
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2026
10/11/2026
Disclosure of Share Capital and Voting Rights Outstanding as of October 31, 2026 (Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des [...]
Informations relatives au nombre total de droits de vote et d’actions composant le capital
10/11/2026
Nantes, le 10 novembre 2026 – En application de l’article L. 233-8 II du Code de commerce et de l’article 223-16 du Règlement général de l’AMF, OSE Immunotherapeutics (ISIN : FR0012127173 ; Mnémo : OSE), une société de [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 octobre 2026
10/11/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
Krystal Biotech to Present at Upcoming Investor Conferences
10/11/2026
PITTSBURGH, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) today announced that management will take part in fireside chats and host investor meetings at the following conferences [...]
AchieveRx Reports Third Quarter 2026 Financial Results and Provides Business Updates
10/11/2026
Launched new corporate brand as AchieveRx, The Quit Company (Nasdaq: QUIT) Presented 52-week ORCA-OL data at the CHEST 2026 Annual Meeting showing that nearly one in three adults still smoking or vaping after a [...]
Paragon Genomics and Intelliseq Partner to Accelerate High-Throughput Pharmacogenomic Profiling
10/11/2026
Learn more about the unique PGx capabilities enabled by the collaboration in an Innovation Spotlight presentation at AMP 2026 on November 13, 2026 FREMONT, Calif. and MURRIETA, Calif., Nov. 10, 2026 (GLOBE NEWSWIRE) -- [...]
Corbus Pharmaceuticals Reports Q3 2026 Financial Results and Provides a Corporate Update
10/11/2026
Dosed first patient in TEMPO-1 registrational study of sutantatug envedotin (CRB-701) in patients with 2L+ oropharyngeal cancer Reported topline data from the CANYON-1 Phase 1b obesity study of CRB-913 demonstrating [...]

Pages

Other news

Test 2

Lorem ipsum

Test 1

Lorem upsum